Abstract
Objective To characterize the clinical features of children and adolescents hospitalized with SARS-CoV-2 infections and to explore predictors for disease severity.
Design Nationwide prospective observational cohort study.
Setting Data collected from 169 out of 351 children’s hospitals in Germany between March 18, 2020 and April 30, 2021 and comparison with the Statutory Notification System.
Participants 1,501 children and adolescents up to 19 years of age with laboratory confirmed SARS-CoV-2 infections who were admitted to children’s hospitals and subsequently reported to the COVID-19 registry of the German Pediatric Infectious Disease Society (DGPI).
Main outcome measures Admission to intensive care, in-hospital.
Results As compared to the information in the statutory notification system, up to 30% of all children and adolescents hospitalized in Germany during the study period were reported to the DGPI registry. Median age was three years (IQR, 0-12), with 36% of reported cases being infants. Although roughly half of patients in the registry were not admitted to the hospital due to their SARS-CoV-2 infection, 72% showed infection-related symptoms during hospitalization. Preexisting comorbidities were present in 28%, most commonly respiratory disorders, followed by neurological, neuromuscular, and cardiovascular diseases. Median length of hospitalization was five days (IQR 3-10). Only 20% of patients received a SARS-CoV-2-related therapy. Infants were less likely to require therapy as compared to older children. Overall, 111 children and adolescents were admitted to intensive care units (ICU). In a fully adjusted model, patient age, trisomy 21, coinfections and primary immunodeficiencies (PID) were significantly associated with intensive care treatment. In a bivariate analysis, pulmonary hypertension, cyanotic heart disease, status post (s/p) cardiac surgery, fatty liver disease, epilepsy and neuromuscular impairment were statistically significant risk factors for ICU admission.
Conclusion Overall, a small proportion of children and adolescents was hospitalized in Germany during the first year of the pandemic. The majority of patients within our registry was not admitted due to COVID-19 suggesting an overestimation of the disease burden even in hospitalized children. Nevertheless, a large proportion of children and adolescents with confirmed COVID-19 reported in Germany could be captured. This allowed for detailed assessment of overall disease severity and underlying risk factors in our cohort. The main risk factors for COVID-19 disease associated intensive care treatment were older patient age, trisomy 21, PIDs and coinfection at the time of hospitalization.
Trial registration Registry of hospitalized pediatric patients with SARS-CoV-2 infection (COVID-19), DRKS00021506
Competing Interest Statement
Reinhard Berner and Jakob P. Armann report grants from the Federal State of Saxony during the conduct of the study. Jochen Schmitt received institutional funding for investigator-initiated research from Novartis, Sanofi, Pfizer, ALK, and acted as a consultant for Novartis, Sanofi, and Lilly unrelated to this study. The other authors have no conflicts of interest to disclose.
Clinical Trial
DRKS00021506
Funding Statement
This study was supported in part by a grant by the Federal State of Saxony. The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report and in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the Technische Universitaet (TU) Dresden (BO-EK-110032020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We share data if reasonable requests are received. Requests should be directed to the corresponding author at Jakob.armann@uniklinikum-dresden.de
Abbreviations
- CI
- Confidence interval
- COVID-19
- Coronavirus disease 2019
- RTA
- Rapid antigen test
- PID
- Primary Immunodeficiency
- ICU
- Intensive care unit
- h/o
- History of
- s/p
- Status post
- IQR
- Interquartile Range
- MIS-C
- Multisystem Inflammatory Syndrome in Children
- PCR
- Polymerase Chain Reaction
- PIMS
- Pediatric Inflammatory Multisystem Syndrome
- SARS-CoV-2
- Severe acute respiratory syndrome Coronavirus type 2
